Editorial companion

What stands out

Schwab Network led with a simple, high-stakes observation: Merck and Moderna both popped after positive melanoma vaccine news, and analysts are openly split on whether those moves are durable. That matters because the two stocks could not be more different under the hood, Merck carries steady revenue with large, lumpy profit swings while Moderna is recovering from a collapse in vaccine sales but has seen a speculative, momentum-driven surge. The segment paired those biotech headlines with real-economy color from Advance Auto Parts and Deere, reminding investors one part of the market lives off clinical readouts and another off construction cycles.